BASF and Eight Partners Cooperate to Optimize Production Processes for Renewable-Based Products
A consortium of companies in the European process industry from the areas of biotechnology, renewable resources, chemistry, process engineering, equipment supply, as well as research organizations recently launched project PRODIAS (PROcessing Diluted Aqueous Systems). The project focuses on unlocking the potential of renewable-based products made via white biotechnology, by significantly decreasing production costs, increasing productivity and efficiency, lowering energy consumption, and accelerating process developments.
Under the consortial leadership of BASF, the partners include Cargill Haubourdin, France; University of Kaiserslautern, Germany; Imperial College London, UK; Alfa Laval, Sweden; GEA Messo PT, the Netherlands; Xendo, the Netherlands; UPM, Finland; and Enviplan, Germany. These partners will collaborate to develop cost and energy-efficient technologies for water purification, removal and product-recovery needed to support downstream processing in white biotechnology.
Using biotechnological methods such as fermentation or biocatalysis, in most cases the renewable-based products are produced as part of complex dilute aqueous mixtures from which they have to be purified. This includes the removal of a vast amount of water, making the downstream process energy intensive as it often requires many complex consecutive separation steps and thus hampers the cost-competitiveness of products from renewable resources. Furthermore, processing methods developed for chemical production are often used which are insufficiently adapted to biotechnological processes.
PRODIAS aims to address these challenges by developing and implementing cost-effective separation and purification technologies tailored for renewable resources in white biotechnology production processes. Its focus is to adapt separation techniques to the need of white biotechnology products and to design novel hybrid systems combining individual advantages, for example, selectivity and energy efficiency. The bioreactions (fermentations) and biocatalysis by which the valuable products are produced are subject to alteration and optimization, to enable more efficient and resource-saving downstream processing.
The total project budget is about €14 million with the European Union contributing €10 million. EU funding of the PRODIAS project is enabled via the Public-Private Partnership with SPIRE (Sustainable Process Industry through Resource and Energy Efficiency). SPIRE, in turn, is part of Horizon 2020, the EU framework program for research and innovation, which runs from 2014 to 2020 and comprises an €80 billion budget. In partnership with industry, the EU will invest in innovative technologies for sustainable processes.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...